An in Vitro Combined Antibiotic-antibody Treatment Eliminates Toxicity from Shiga Toxin-producing Escherichia Coli

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2015 Jun 24

PMID 26100707

Citations 9

Authors

Craig Skinner

Guodong Zhang

Stephanie Patfield

Xiaohua He

Affiliations

Soon will be listed here.

Abstract

Treating Shiga toxin-producing Escherichia coli (STEC) gastrointestinal infections is difficult. The utility of antibiotics for STEC treatment is controversial, since antibiotic resistance among STEC isolates is widespread and certain antibiotics dramatically increase the expression of Shiga toxins (Stxs), which are some of the most important virulence factors in STEC. Stxs contribute to life-threatening hemolytic uremic syndrome (HUS), which develops in considerable proportions of patients with STEC infections. Understanding the antibiotic resistance profiles of STEC isolates and the Stx induction potential of promising antibiotics is essential for evaluating any antibiotic treatment of STEC. In this study, 42 O157:H7 or non-O157 STEC isolates (including the "big six" serotypes) were evaluated for their resistance against 22 antibiotics by using an antibiotic array. Tigecycline inhibited the growth of all of the tested STEC isolates and also inhibited the production of Stxs (Stx2 in particular). In combination with neutralizing antibodies to Stx1 and Stx2, the tigecycline-antibody treatment fully protected Vero cells from Stx toxicity, even when the STEC bacteria and the Vero cells were cultured together. The combination of an antibiotic such as tigecycline with neutralizing antibodies presents a promising strategy for future STEC treatments.

Citing Articles

A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.

Kirkland M, Patfield S, Hughes A, Hernlem B, He X Antimicrob Agents Chemother. 2023; 68(1):e0059823.

PMID: 38047751 PMC: 10777836. DOI: 10.1128/aac.00598-23.

Tigecycline Suppresses the Virulence Factors of Multidrug-Resistant Allowing Human Neutrophils to Act.

Sato Y, Hatayama N, Ubagai T, Tansho-Nagakawa S, Ono Y, Yoshino Y Infect Drug Resist. 2022; 15:3357-3368.

PMID: 35789794 PMC: 9250330. DOI: 10.2147/IDR.S368890.

Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives.

Henrique I, Sacerdoti F, Ferreira R, Henrique C, Amaral M, Piazza R Front Cell Infect Microbiol. 2022; 12:825856.

PMID: 35223548 PMC: 8866733. DOI: 10.3389/fcimb.2022.825856.

Risk of Hemolytic Uremic Syndrome Related to Treatment of O157 Infection with Different Antimicrobial Classes.

Mody R, Hoekstra R, Scott M, Dunn J, Smith K, Tobin-DAngelo M Microorganisms. 2021; 9(9).

PMID: 34576892 PMC: 8466573. DOI: 10.3390/microorganisms9091997.

Potentiation of Antibiotics by a Novel Antimicrobial Peptide against Shiga Toxin Producing E. coli O157:H7.

Puno-Sarmiento J, Anderson E, Park A, Khursigara C, Barnett Foster D Sci Rep. 2020; 10(1):10029.

PMID: 32572054 PMC: 7308376. DOI: 10.1038/s41598-020-66571-z.

References

Bitzan M, Klemt M, Steffens R, Muller-Wiefel D . Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls. Infection. 1993; 21(3):140-5. DOI: 10.1007/BF01710530. View

Muniesa M, Hammerl J, Hertwig S, Appel B, Brussow H . Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology. Appl Environ Microbiol. 2012; 78(12):4065-73. PMC: 3370534. DOI: 10.1128/AEM.00217-12. View

Silva-Sanchez J, Reyna-Flores F, Velazquez-Meza M, Rojas-Moreno T, Benitez-Diaz A, Sanchez-Perez A . In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study. Diagn Microbiol Infect Dis. 2011; 70(2):270-3. DOI: 10.1016/j.diagmicrobio.2010.12.018. View

Friedrich A, Bielaszewska M, Zhang W, Pulz M, Kuczius T, Ammon A . Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis. 2002; 185(1):74-84. DOI: 10.1086/338115. View

Fraser M, Fujinaga M, Cherney M, Melton-Celsa A, Twiddy E, OBrien A . Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem. 2004; 279(26):27511-7. DOI: 10.1074/jbc.M401939200. View

Singh R, Schroeder C, Meng J, White D, McDermott P, Wagner D . Identification of antimicrobial resistance and class 1 integrons in Shiga toxin-producing Escherichia coli recovered from humans and food animals. J Antimicrob Chemother. 2005; 56(1):216-9. DOI: 10.1093/jac/dki161. View

Scotland S, Willshaw G, Smith H, Rowe B . Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect. 1987; 99(3):613-24. PMC: 2249237. DOI: 10.1017/s0950268800066462. View

Jitkova Y, Gronda M, Hurren R, Wang X, Goard C, Jhas B . A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. PLoS One. 2014; 9(5):e95281. PMC: 4037176. DOI: 10.1371/journal.pone.0095281. View

Probert W, McQuaid C, Schrader K . Isolation and identification of an Enterobacter cloacae strain producing a novel subtype of Shiga toxin type 1. J Clin Microbiol. 2014; 52(7):2346-51. PMC: 4097712. DOI: 10.1128/JCM.00338-14. View

10.

Canizalez-Roman A, Gonzalez-Nunez E, Vidal J, Flores-Villasenor H, Leon-Sicairos N . Prevalence and antibiotic resistance profiles of diarrheagenic Escherichia coli strains isolated from food items in northwestern Mexico. Int J Food Microbiol. 2013; 164(1):36-45. DOI: 10.1016/j.ijfoodmicro.2013.03.020. View

11.

Rasooly R, Do P . Shiga toxin Stx2 is heat-stable and not inactivated by pasteurization. Int J Food Microbiol. 2009; 136(3):290-4. DOI: 10.1016/j.ijfoodmicro.2009.10.005. View

12.

He X, Patfield S, Hnasko R, Rasooly R, Mandrell R . A polyclonal antibody based immunoassay detects seven subtypes of Shiga toxin 2 produced by Escherichia coli in human and environmental samples. PLoS One. 2013; 8(10):e76368. PMC: 3797811. DOI: 10.1371/journal.pone.0076368. View

13.

He X, McMahon S, Skinner C, Merrill P, Scotcher M, Stanker L . Development and characterization of monoclonal antibodies against Shiga toxin 2 and their application for toxin detection in milk. J Immunol Methods. 2013; 389(1-2):18-28. DOI: 10.1016/j.jim.2012.12.005. View

14.

Scholl D, Gebhart D, Williams S, Bates A, Mandrell R . Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen. PLoS One. 2012; 7(3):e33637. PMC: 3303846. DOI: 10.1371/journal.pone.0033637. View

15.

Scheutz F, Teel L, Beutin L, Pierard D, Buvens G, Karch H . Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol. 2012; 50(9):2951-63. PMC: 3421821. DOI: 10.1128/JCM.00860-12. View

16.

Tesh V, OBrien A . The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. Mol Microbiol. 1991; 5(8):1817-22. DOI: 10.1111/j.1365-2958.1991.tb00805.x. View

17.

Eng R, Smith S, Fan-Havard P, Ogbara T . Effect of antibiotics on endotoxin release from gram-negative bacteria. Diagn Microbiol Infect Dis. 1993; 16(3):185-9. DOI: 10.1016/0732-8893(93)90109-k. View

18.

Plunkett 3rd G, Rose D, Durfee T, Blattner F . Sequence of Shiga toxin 2 phage 933W from Escherichia coli O157:H7: Shiga toxin as a phage late-gene product. J Bacteriol. 1999; 181(6):1767-78. PMC: 93574. DOI: 10.1128/JB.181.6.1767-1778.1999. View

19.

Frank C, Werber D, Cramer J, Askar M, Faber M, An der Heiden M . Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011; 365(19):1771-80. DOI: 10.1056/NEJMoa1106483. View

20.

Du X, Fu Y, Yu Y . Tigecycline treatment of infection caused by KPC-producing Escherichia coli in a pediatric patient. Ann Clin Microbiol Antimicrob. 2013; 12:19. PMC: 3851780. DOI: 10.1186/1476-0711-12-19. View